Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia

Détails

ID Serval
serval:BIB_A154D5A1FF1A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia
Périodique
Dermatology
Auteur(s)
Gambillara  E., Laffitte  E., Widmer  N., Decosterd  L. A., Duchosal  M. A., Kovacsovics  T., Panizzon  R. G.
ISSN
1018-8665 (Print)
Statut éditorial
Publié
Date de publication
2005
Peer-reviewed
Oui
Volume
211
Numéro
4
Pages
363-365
Langue
anglais
Notes
Case Reports Journal Article
Résumé
Imatinib is a specific and potent inhibitor of the BCR-ABL tyrosine kinase. Several clinical trials have demonstrated the efficacy of imatinib in chronic myeloid leukemia. Adverse cutaneous reactions induced by imatinib are frequent and may be dose related. We report a case of an unusual pustular eruption in a patient with chronic myeloid leukemia, who received high doses imatinib for blast crisis and later voriconazole for invasive pulmonary aspergillosis. At the time of his skin eruption, elevated plasma levels of imatinib were recorded. Imatinib is primarily metabolized by the cytochrome CYP3A4. Voriconazole is a cytochrome CYP3A4 inhibitor and can lead to high plasma levels of imatinib. This case suggests that severe drug reactions to imatinib may be related not only to imatinib doses, but also to elevated plasma drug levels resulting from pharmacokinetic interactions. The monitoring of imatinib plasma levels may be of help for identifying patients at risk for severe toxicity.
Mots-clé
Adult Antifungal Agents/*adverse effects Antineoplastic Agents/*adverse effects/blood Aspergillosis/drug therapy Cytochrome P-450 Enzyme System/antagonists & inhibitors Drug Eruptions/*etiology Drug Interactions Enzyme Inhibitors/adverse effects Exanthema/*chemically induced Humans Irritants/*adverse effects Leukemia, Myeloid, Chronic/*drug therapy Lung Diseases, Fungal/drug therapy Male Piperazines/*adverse effects/blood Protein-Tyrosine Kinases/*antagonists & inhibitors Pyrimidines/*adverse effects/blood Triazoles/*adverse effects
Pubmed
Web of science
Création de la notice
25/01/2008 15:24
Dernière modification de la notice
20/08/2019 15:07
Données d'usage